3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
18
Unknown
12
Recruiting
10
Not yet recruiting
4
Terminated
2
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Breast
2
Thoracic
1
Dermatologic
1
Conditions
Breast Neoplasms
989
Neoplasms
848
Carcinoma, Non-Small-Cell Lung
842
Prostatic Neoplasms
527
Neoplasm Metastasis
500
Leukemia, Myeloid, Acute
488
Melanoma
453
Colorectal Neoplasms
446
Multiple Myeloma
440
Lung Neoplasms
419
Pancreatic Neoplasms
352
Recurrence
350
Lymphoma
349
Ovarian Neoplasms
341
Lymphoma, Non-Hodgkin
327
Leukemia
323
Leukemia, Lymphocytic, Chronic, B-Cell
301
Precursor Cell Lymphoblastic Leukemia-Lymphoma
271
Carcinoma, Renal Cell
256
Head and Neck Neoplasms
246
Brain Neoplasms
243
Carcinoma, Hepatocellular
234
Squamous Cell Carcinoma of Head and Neck
231
Glioblastoma
231
Myelodysplastic Syndromes
229
Lymphoma, Large B-Cell, Diffuse
228
Lymphoma, Follicular
219
Colonic Neoplasms
191
Stomach Neoplasms
182
Rectal Neoplasms
175
Interventions
Temozolomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Interventional
×
Neoplasms, Second Primary
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts
NCT00629187
2012-04-27
CN-306
Tufts Medical Center
Phase 1
Terminated
2 enrolled